SINOMAB BIO-B (03681) has announced that on July 24, 2026, the company granted 18.026 million share options to two eligible individuals.
This grant was made under the share option scheme previously adopted at a special general meeting on October 26, 2022, and subsequently amended at the annual general meeting held on June 14, 2024.
Each option entitles the holder to subscribe for one share of the company. The options entitle the grantees to subscribe for a total of 18.026 million shares, subject to acceptance by the grantees.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.